Subscribe
  
IPQ Inside the global regulatory dialogue

Archive for ‘October, 2010’

Increasing Cargo Theft of Pharmaceuticals May Have Brand Impact and Result in Recalls

The significant increase in pharmaceutical cargo thefts in the US carries hidden consequences for drug firms beyond the dollar loss they incur, including damaged reputations and the need to perform product recalls....
October 29, 2010 | Posted in Diversion, Shipping & Storage, Supply Chain/GDPs, The News in Depth, US/Canada | Read More »

New Warning Letters in US Focus on Process Validation and Sponsor/Contractor Relations

Drug GMP warning letters issued in mid-October to Hauppage, New York-based Contract Pharmacal and to Advanced Testing Laboratory in Cincinnati, Ohio shed light on FDA’s compliance expectations for two front-burner issues – process validation and sponsor/contractor communications....
October 28, 2010 | Posted in GMP Deviations/Warning Letters, GMP Enforcement Activity, Oral, The News in Depth, US/Canada | Read More »

FDA, USP and CHPA Team Up to Address OTC Drug Impurity Problems

A committee comprised of experts representing FDA, the US Pharmacopeia (USP) and the Consumer Healthcare Products Association (CHPA) is considering how to strengthen the control of impurities in over-the-counter (OTC) products....
October 26, 2010 | Posted in CMC Standards, OTC, Purity/Potency/Identity/Stability, The News in Depth, US/Canada | Read More »

Laboratory Control Issues Prominent in Recent Warning Letters to Four Overseas Firms

Laboratory control problems are prominent in a bolus of FDA drug GMP warning letters recently issued to companies in Asia and Europe....
October 24, 2010 | Posted in API, Asia, Europe, GMP Deviations/Warning Letters, GMP Enforcement Activity, Oral, The News in Depth | Read More »

FDA Wants More Transparency on Drug Recall Data and Causes

FDA is looking to create more transparency around the data it collects on product recalls and their underlying causes....
October 20, 2010 | Posted in GMP Enforcement Activity, Recalls, The News in Depth, US/Canada | Read More »

FDA-Wide Effort Underway to Clarify and Harmonize CAPA Definitions in Line with New GHTF Guide

FDA Center for Devices and Radiological Health (CDRH) GMP expert Kimberly Trautman is spearheading an effort to clean up and harmonize the definitions around corrective and preventive action (CAPA) across the agency in line with a Global Harmonization Task Force (GHTF) guideline on CAPA that is nearing release....
October 19, 2010 | Posted in GMP Policy, OOS/CAPA, The News in Depth, US/Canada | Read More »

Australia’s TGA Publishes Updated Draft Guidance on Clearance of Products Manufactured Overseas

TGA has released for comment a draft guideline that clarifies its requirements for GMP compliance by overseas manufacturers and further harmonizes those requirements with other international regulatory bodies....
October 18, 2010 | Posted in Australia, CMC Review Policy, General, Marketing Application/General, Supply Chain/GDPs, The News in Depth | Read More »

FDA Raises Tablet Contractor Validation, Aseptic Processing Concerns at Gilead

Tablet contractor process revalidation and aseptic processing of injectible AmBisome were areas of concern addressed in a warning letter from FDA’s Los Angeles District office to San Dimas, CA-based Gilead Sciences in late September....
October 16, 2010 | Posted in GMP Deviations/Warning Letters, GMP Enforcement Activity, Injectable, Oral, The News in Depth, US/Canada | Read More »

China’s SFDA Moving Toward Expanding Supply Chain Auditing and Filing Requirements

China’s State Food and Drug Administration (SFDA) has released a draft of a new regulation that would significantly expand the supply chain auditing and filing requirements for manufacturers of active pharmaceutical ingredients (APIs) and packaging as well as drug products....
October 11, 2010 | Posted in Asia, General, Supply Chain/GDPs, The News in Depth | Read More »

The Combination of GMP & Unapproved Drug Problems Continues to Prompt FDA Warning Letters

Warning letters to a pair of over-the-counter (OTC) drug manufacturers just released by FDA indicate that the marketing of unapproved drugs continues to escalate the agency’s response when GMP problems are found....
October 8, 2010 | Posted in GMP Deviations/Warning Letters, GMP Enforcement Activity, OTC, The News in Depth, US/Canada, Unapproved Drugs | Read More »
Pages: 1 2 Next

Subscriber Login



Subscription Benefits

Subscribe today and get 24/7 access to the IPQ family of publications:

.

  • “In the News” — breaking stories on our website
  • “Weekly News Alert” — sent via email
  • “Monthly Update” — the key CMC and GMP developments in the US, Europe and internationally
  • “Special Reports” — in-depth analysis of specific, emerging issues of regulator/industry concern
  • Documents and Archives — Live links to all the documents referenced in our stories and full access to IPQ’s valuable archive library

.

Click to Enlarge

Click here for the January Monthly Update

IPQ’s Mission

IPQ is dedicated to helping advance the dialogue on evolving and harmonizing the regulation of pharmaceutical and biologic quality and manufacturing.

.

IPQ takes its readers from:

  • ● the headlines to the forces driving them
  • ● regulations and policies to their underlying intent
  • ● the pieces of the puzzle to their interconnection
  • ● requirements to implementation pathways
  • ● random data to critical trends
  • ● the sidelines to helping shape the outcome
  • ● compliance problems to proactive quality tools
  • ● information to intelligence

.

Subscribe today and get 24/7 access to the IPQ family of publications: “In the News” — breaking stories on our website; “Weekly News Alert” — sent via email; “Monthly Update” — the key CMC and GMP developments in the US, Europe and internationally; “Special Reports” — in-depth analysis of specific, emerging issues of regulator/industry concern; and Documents and Archives — live links to all the documents referenced in our stories and full access to IPQ’s valuable archive library.



©2012 IPQ Publications